Notable is combining existing, de-risked drugs with a proprietary predicted responder diagnostic to create novel Presponse™ therapeutics. We have designed our research pipeline to dramatically increase the clinical response rates of our therapeutics while reducing the risk, time and cost of development by identifying and treating only those patients who are most likely to benefit.
Our lead program, Ntbl-201 (Volasertib + PRD-AML), is in-licensed with exclusive worldwide development and commercialization rights except for certain rare pediatric cancers. Volasertib was originally developed by Boehringer Ingelheim through Phase 3. Notable in-licensed the asset following extensive Boehringer Ingelheim post hoc analysis and strong performance on the Notable Predictive Medicine Platform.
